The rise of GLP-1 agonists is revolutionizing obesity management, but has revealing a major aesthetic side effect in clinical practice, the so-called « GLP-1 Face » or « Ozempic Face. » At ExAdEx-Innov, we decode these mechanisms using our exclusive ex vivo model of human facial adipose tissue.
« GLP-1 Face » refers to the rapid facial volume loss seen in patients on GLP-1 agonists, characterized by:
This goes beyond simple weight loss: it’s a tissue reprogramming involving adipocyte modulation, stiffening, and residual inflammation.
With millions of GLP-1 patients, the demand is exploding: restore volume, elasticity, and skin quality without compromising metabolic benefits.
Traditional 2D/3D models fail in testing these effects and reconstructed organ-like models cannot mimic the holistic yet tailored effect of GLP-1 agonists on facial adipose tissue. Only functional human tissue enables predictive testing.
Thanks to the exclusive use of our patented ExAdEx technology and to a clinically relevant approach with our medical advisory team, we are the only provider of complete ex vivo human facial hypodermal tissue models: mature size and functional adipocytes, complete natural extracellular matrix, preserved vascularization, neuro-hypodermis interactions.
Beauty, cosmetics, aesthetic medicine devices or pharma professionals developing solutions to target GLP-1 facial outcomes? Test them on our facial ex vivo models to validate anti-« Ozempic Face » efficacy.
Follow us on LinkedIn for the latest advances and contact us for more information.
ExAdEx-Innov contributes to a publication on adipose tissue processing ExAdEx-Innov is proud to contribute to a new collaborative study published in Scientific Reports, a journal
ExAdEx-Innov proudly contributed to the 19th International Symposium “Cosmetic Science: Shaping the Future” organized by the Société Française de Cosmétologie (SFC) in Paris on December
EXADEX-INNOV is excited to announce that Resalis Therapeutics will present preclinical translational data at Obesity Week 2025, including results obtained on our human adipose tissue
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management
